A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA
Mad in America
AUGUST 14, 2024
Or perhaps the rejection of Lykos’ drug reveals something else: the powerful influence of the traditional pharmaceutical lobby at the cost of the upstart psychedelic industry. That is surely a problem, but it’s also a documented problem for other drugs. We may never know. Where Might This All Lead?
133 
Let's personalize your content